Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results Alexa B. Kimball,

Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Efficacy of simvastatin in plaque psoriasis: A pilot study

Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis Federica Ricceri, MD, Leonardo.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid- Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched,

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Assessing adherence with phototherapy protocols

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Applying for dermatology residency is difficult and expensive

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies Linda.

Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Treatment of psoriasis vulgaris using low-dose naltrexone

Increased serum levels of interleukin 33 in patients with atopic dermatitis Risa Tamagawa-Mineoka, MD, PhD, Yasutaro Okuzawa, MD, Koji Masuda, MD, PhD,

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Safety and efficacy of hydrogen peroxide topical solution, 40% (w/w), in patients with seborrheic keratoses: Results from 2 identical, randomized, double-blind,

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis Kristian Reich,

Lip edema Journal of the American Academy of Dermatology

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis” Kristian Reich, Craig Leonardi,

Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis Stephen R. Durham,

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial Alice Gottlieb, MD, PhD, John Sullivan,

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks Esther von Stebut, Kristian.

Alan Menter, MD, Stephen K

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of oxymetazoline cream 1

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne Jerry Tan, MD, Diane Thiboutot, MD, Georg Popp,

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid- Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched,

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Adapalene gel 0.3% for the treatment of acne vulgaris: A multicenter, randomized, double-blind, controlled, phase III trial Diane Thiboutot, MD, David.

Presentation transcript:

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant Thaçi, MD, Andrew Blauvelt, MD, MBA, Kristian Reich, MD, Tsen-Fang Tsai, MD, Francisco Vanaclocha, MD, Külli Kingo, MD, PhD, Michael Ziv, MD, BSc, Andreas Pinter, MD, Sophie Hugot, MSc, Ruquan You, MSc, Marina Milutinovic, MD Journal of the American Academy of Dermatology Volume 73, Issue 3, Pages 400-409 (September 2015) DOI: 10.1016/j.jaad.2015.05.013 Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Study design. aTo maintain blinding, placebo injections matching the secukinumab regimen were given to subjects in the ustekinumab group. Journal of the American Academy of Dermatology 2015 73, 400-409DOI: (10.1016/j.jaad.2015.05.013) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Subject disposition. ∗Four subjects did not receive study treatment (2 withdrew consent; 1 because of technical problem; and 1 because of physician decision) and discontinued the study at randomization; 1 subject was excluded from all analyses because the informed consent form was obtained the day after study-related procedure. †In all, 25 subjects discontinued study treatment because of adverse event (7); lost to follow-up (3); protocol deviation (5); subject/guardian decision (7); physician decision (1); noncompliance with study treatment (1); and technical problem (1). Journal of the American Academy of Dermatology 2015 73, 400-409DOI: (10.1016/j.jaad.2015.05.013) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Efficacy over time to week 16. Improvement from baseline Psoriasis Area and Severity Index (PASI) score of 90% or more (PASI 90) (A), 100% (PASI 100) (B), or 75% or more (PASI 75) (C). D, Investigator global assessment 2011 modified version (IGA mod 2011) 0/1 response. E, Dermatology Life Quality Index (DLQI) 0/1 response. ∗P ≤ .0001, †P < .001, ‡P < .05. Missing values for PASI score response variables and IGA mod 2011 0/1 response were imputed as nonresponses (nonresponder imputation). Only subjects who could be evaluated for a response were included (subjects who had missed all postbaseline values were excluded for that response variable). Missing values for DLQI were handled using last observation carried forward. Journal of the American Academy of Dermatology 2015 73, 400-409DOI: (10.1016/j.jaad.2015.05.013) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions